$497 Million is the total value of Meditor Group Ltd's 9 reported holdings in Q2 2019. The portfolio turnover from Q1 2019 to Q2 2019 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| EXEL | Sell | EXELIXIS INC | $320,572,000 | -10.8% | 15,001,073 | -0.6% | 64.48% | -4.3% |
| ESPR | ESPERION THERAPEUTICS INC | $124,665,000 | +15.9% | 2,679,835 | 0.0% | 25.08% | +24.3% | |
| ALKS | ALKERMES PLC | $20,114,000 | -38.2% | 892,400 | 0.0% | 4.05% | -33.7% | |
| INDA | ISHARES MSCI INDIA ETF | $11,296,000 | +0.1% | 320,000 | 0.0% | 2.27% | +7.4% | |
| EPI | WISDOMTREE INDIA EARNINGS FUND | $10,424,000 | -1.0% | 400,000 | 0.0% | 2.10% | +6.2% | |
| SDS | PROSHARES ULTRASHORT S&P 500 ETF | $3,532,000 | -7.7% | 115,000 | 0.0% | 0.71% | -1.1% | |
| SPXU | PROSHARES ULTRAPRO SHORT S&P 500 ETF | $2,921,000 | -11.8% | 105,000 | 0.0% | 0.59% | -5.3% | |
| SQQQ | Sell | PROSHARES ULTRAPRO SHORT QQQ ETF | $2,504,000 | -13.6% | 71,250 | -75.0% | 0.50% | -7.2% |
| CLDX | CELLDEX THERAPEUTICS | $1,127,000 | -45.6% | 420,846 | 0.0% | 0.23% | -41.5% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-07-24
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| EXELIXIS INC | 43 | Q4 2023 | 88.9% |
| ALKERMES PLC | 31 | Q4 2020 | 62.6% |
| ISHARES MSCI INDIA ETF | 31 | Q4 2023 | 5.5% |
| WISDOMTREE INDIA EARNINGS FUND | 31 | Q4 2023 | 5.5% |
| ESPERION THERAPEUTICS INC | 27 | Q4 2023 | 34.4% |
| VIVUS INC | 15 | Q4 2016 | 21.3% |
| CELLDEX THERAPEUTICS | 14 | Q2 2020 | 2.7% |
| PROSHARES ULTRAPRO SHORT S&P500 | 4 | Q4 2017 | 3.8% |
| PROSHARES ULTRASHORT S&P500 | 4 | Q4 2017 | 3.0% |
| PROSHARES ULTRASHORT S&P 500 ETF | 3 | Q3 2019 | 0.8% |
View Meditor Group Ltd's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| EXELIXIS, INC. | April 09, 2019 | 15,001,073 | 5.0% |
| VIVUS INC | December 19, 2012 | 5,002,896 | 5.0% |
| VIVUS INC | March 21, 2012 | 6,177,500 | 6.3% |
| VION PHARMACEUTICALS INC | February 15, 2008 | 5,736,200 | 7.6% |
| CYPRESS BIOSCIENCE INC | September 26, 2007 | 1,864,645 | 5.0% |
| ONYX PHARMACEUTICALS INC | September 12, 2007 | 2,627,800 | 4.8% |
| ACUSPHERE INC | July 26, 2007 | 1,839,421 | 4.0% |
| NOVACEA INC | June 11, 2007 | 800,000 | 3.4% |
| ATHEROGENICS INC | May 02, 2007 | 1,361,800 | 3.5% |
View Meditor Group Ltd's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-04-11 |
| 13F-HR | 2024-01-04 |
| SC 13G/A | 2024-01-03 |
| 13F-HR | 2023-10-31 |
| 13F-HR | 2023-07-25 |
| 13F-HR | 2023-04-10 |
| 13F-HR | 2023-01-05 |
| SC 13G/A | 2023-01-04 |
| 13F-HR | 2022-11-07 |
| 13F-HR | 2022-07-18 |
View Meditor Group Ltd's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.